Introduction Kerendia is the brand name for finerenone, a non-steroidal selective mineralocorticoid receptor antagonist (MRA) used to reduce the risk of chronic kidney disease (CKD) progression and cardiovascular complications in adults with chronic kidney disease associated with type 2 diabetes mellitus. Unlike older steroidal MRAs such as spironolactone and eplerenone, finerenone has a unique non-steroidal … Read more
Introduction Dapagliflozin (trade name Farxiga) is a sodium–glucose co‑transporter 2 (SGLT2) inhibitor used in type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF). It lowers blood glucose by promoting renal excretion of glucose and also provides cardiovascular and renal benefits beyond glycemic control. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral … Read more
Introduction Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) approved for reducing the risk of cardiovascular and renal events in adults with chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM). Unlike steroidal MRAs such as spironolactone, finerenone offers greater mineralocorticoid receptor selectivity, minimizing off-target hormonal effects. Step-by-Step Mechanism of Action Pharmacokinetic … Read more
